CJC-1295 vs Sermorelin: GHRH Analog Comparison
CJC-1295 is a synthetic GHRH (growth hormone-releasing hormone) analog available in two forms: with DAC (Drug Affinity Complex) providing an extended 8-day half-life for sustained GH elevation, and without DAC (mod-GRF 1-29) for pulsatile GH release. Sermorelin is the first 29 amino acids of natural GHRH, previously FDA-approved for pediatric growth hormone deficiency, with the most human clinical data among GHRH analogs. Both stimulate endogenous GH production through the GHRH receptor but differ significantly in half-life, dosing frequency, and GH release patterns.
Side-by-Side Comparison
| Parameter | CJC-1295 | Sermorelin |
|---|---|---|
| Mechanism | GHRH receptor agonist (synthetic analog) | GHRH receptor agonist (natural GHRH 1-29) |
| Evidence Grade | B+ | A- |
| Half-Life | ~8 days (with DAC); ~30 min (no DAC) | ~10-20 minutes |
| Route | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 2 mg/week (DAC); 100 mcg 2-3x/day (no DAC) | 200 - 300 mcg before bed daily |
| GH Release Pattern | Sustained elevation (DAC); pulsatile (no DAC) | Pulsatile (mimics natural secretion) |
| Dosing Frequency | 2-3x/week (DAC); daily (no DAC) | Daily (typically before bed) |
| Best For | Sustained IGF-1 elevation, convenience | Natural GH pulsatility, clinical-grade research |
| FDA Status | Not FDA-approved; research compound | Previously FDA-approved (Geref); withdrawn 2008 |
| Cost (research grade) | $$ | $ |
CJC-1295: Pros & Cons
Advantages
- Extended half-life (DAC) allows 2-3x/week dosing
- Sustained GH and IGF-1 elevation
- Strong synergy when combined with GHRP peptides
- Mod-GRF 1-29 (no DAC) preserves pulsatile release
- Well-tolerated in clinical studies
Considerations
- DAC version may desensitize GH receptors over time
- Less human clinical data than sermorelin
- Sustained GH elevation (DAC) is non-physiological
- Not FDA-approved in any formulation
- Higher cost than sermorelin at research grade
Sermorelin: Pros & Cons
Advantages
- Previously FDA-approved with extensive human safety data
- Natural pulsatile GH release pattern
- Available through compounding pharmacies
- Lowest cost GHRH analog
- Best-characterized pharmacokinetics in humans
- Preserves hypothalamic-pituitary feedback
Considerations
- Very short half-life requires daily injection
- Weaker GH pulse amplitude than CJC-1295 (no DAC)
- Requires consistent bedtime dosing for optimal results
- Some users develop antibodies with long-term use
- Withdrawn from market (commercial, not safety reasons)
Which Is Right for Your Research?
Decision Guide
Choose CJC-1295 with DAC if: Your research prioritizes convenience and sustained GH/IGF-1 elevation. The 8-day half-life allows infrequent dosing and provides steady-state GH levels. Best suited for protocols where consistent anabolic signaling is more important than preserving natural pulsatile secretion.
Choose CJC-1295 without DAC (mod-GRF 1-29) if: You want stronger GH pulse amplitude than sermorelin while maintaining pulsatile release. Often paired with a GHRP (like ipamorelin) for synergistic GH secretion. This is the most popular research GHRH analog for combined protocols.
Choose sermorelin if: You prioritize the deepest human safety data, natural physiological GH pulsatility, and the lowest cost. Sermorelin's FDA history and compounding pharmacy availability make it the most accessible and well-characterized GHRH analog for clinical research.
Frequently Asked Questions
CJC-1295 with DAC produces more sustained GH elevation due to its 8-day half-life. Sermorelin mimics natural pulsatile GH release better. CJC-1295 without DAC (mod-GRF 1-29) provides stronger GH pulses than sermorelin while maintaining pulsatility. The choice depends on whether sustained or pulsatile GH release is desired for your research.
CJC-1295 with DAC binds to albumin, extending half-life to ~8 days with sustained, non-pulsatile GH elevation. Without DAC (mod-GRF 1-29) has a 30-minute half-life producing discrete GH pulses. The DAC version requires less frequent dosing but may desensitize receptors, while the non-DAC version preserves natural pulsatile patterns.
Yes, sermorelin (Geref) was FDA-approved in 1997 for diagnostic use and pediatric GH deficiency treatment. It was voluntarily withdrawn in 2008 for commercial reasons, not safety concerns. It remains available as a compounded peptide and has the most human clinical data of any GHRH analog.
Related Protocol Guides
Compare More
Verified Research Suppliers
- ★ LiveWell Peptides — Official Sponsor • cGMP Certified Paid partnership
- Core Peptides — Third-party tested
- Limitless Life Nootropics — Broad catalog
- Biotech Peptides — USA-based
- Amino Asylum — Budget-friendly
Related Tools & Resources
© 2026 Path to Peptides™. For research and educational purposes only. Not medical advice.
Some links on this site may earn a commission at no cost to you.